WeVote
Log In

Bill

Bill

A 3956

Requires cytomegalovirus screening for every newborn

2025 Regular Session Introduced by Andrew Hevesi and 3 co-sponsors

Requires universal CMV screening for every newborn to enable early detection and timely follow-up care, affecting hospitals, labs, families, and public health programs.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 3956

Summary of Bill A 3956 — Requires Cytomegalovirus Screening for Every Newborn

Overview

Bill A 3956, titled “Requires cytomegalovirus screening for every newborn,” is currently in the Health committee stage. Introduced on January 30, 2025, the bill is now referred to the Health committee for consideration.

Purpose and Intent

  • The bill proposes universal screening for cytomegalovirus (CMV) for all newborns.
  • The goal is to enable early detection of congenital CMV infection, which can affect hearing and development, in order to facilitate timely follow-up care and interventions.

Key Provisions (as indicated by the bill’s title and status)

  • Universal CMV screening for every newborn. The bill would mandate that newborns undergo CMV testing.
  • Details on testing methodology, timing (e.g., immediately at birth or within a defined perinatal window), confirmatory testing, treatment pathways, and follow-up protocols are not specified in the provided summary.
  • No dollar amounts, funding sources, or implementation timelines are provided in the available material.

Who Would Be Affected

  • Newborns and their families/guardians.
  • Hospitals, birthing facilities, pediatric and maternal-fetal medicine providers, and clinical laboratories responsible for performing and reporting CMV screening.
  • State and local public health authorities responsible for newborn screening programs and data collection.
  • Potential implications for health insurers and Medicaid/Medicare programs if follow-up and treatment services are required.

Procedural and Timeline Aspects

  • Introduced: January 30, 2025.
  • Legislative actions: Referred to Health on January 30, 2025 (listed twice in the record).
  • Status: Referred to Health; no further committee action details are provided in the current summary.

Sponsors and Related Legislation

  • Primary sponsor: Linda Rosenthal.
  • Cosponsors: Andrew Hevesi (primary sponsor in the cosponsor role), Nily Rozic, Jen Lunsford.
  • Related bills: A 10129 and A 7997 (prior-session) as related New York State assembly measures; S 5454 (companion bill) noted in the companion category (listed twice, indicating cross-chamber counterparts).

Potential Implications and Considerations

  • Public health impact: Earlier identification of congenital CMV could improve outcomes through timely monitoring and intervention.
  • Implementation: Requires assessment of cost, laboratory capacity, data reporting, consent/privacy considerations, and coordination with existing newborn screening programs.
  • Access and equity: Ensuring universal access to follow-up care and therapies across diverse communities.

Next Steps

If enacted, the bill would advance through the committee process, potential amendments, and floor votes. Stakeholders may seek details on funding, implementation timelines, and specific clinical protocols as the bill’s text and fiscal notes become available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.